Table 1.

Clinical features of IgAN patients^a

Diagnosis								Episode of macroscopic hematuria study sample					Last follow-up
Subject	Age	Gender	Biopsy grade	BP	ACEi	eGFR	UP/C	Age	BP	ACEi	eGFR	UP/C	Age	BP	ACEi	eGFR	UP/C
P1	4.6	M	4	106/56	No	120	0.81	4.9	ND	No	ND	1+b	8.0	115/69	No	120	Traceb
P2	8.7	F	4	120/62	No	100	1.00	8.7	101/64	Yes	95	1.44	15.4	113/64	No	113	0.14
P3	11.6	F	4	126/67	No	106	3.65	11.9	114/74	Yes	97	3.48	18.2	119/71	Yes	110	0.42
P4	11.6	M	3	127/77	No	138	0.35	16.0	137/62	Yes	131	217c	20.2	125/73	No	18	ND
P5	8.6	M	2	104/62	No	101	1.44	8.6	91/56	Yes	101	1.93	11.2	104/62	Yes	156	0.82
A1	22.6	F	4	116/69	No	131	0.34	23.6	101/71	No	94	0.68	26.7	120/84	No	58	0.07
A2	25.9	F	4	102/64	ARB	67	0.72	26.0	108/80	Yes	71	0.72	34.8	126/86	Yes	115	0.20
A3	18.9	M	4	150/85	Yes	95	1.85	19.4	141/84	Yes	102	3.49	19.5	148/80	Yes	86	1.65
A4	38.4	M	1	155/63	No	39	ND	40.2	155/70	No	51	0.47	41.8	119/72	Yes	74	ND

^aUP/C, urinary protein/creatinine ratio (milligram protein per milligram creatinine); P, pediatric patient; A, adult patient; ND, not determined; eGFR, estimated glomerular filtration rate (mL/min/1.73m²); MH, macroscopic hematuria. Biopsy grading by the Haas criteria (ref. [33]).

^bSemi-quantitative protein on a Bayer multi-stick; 1+ is equivalent to 30 mg protein/dL—usually a UP/C ratio <0.5.

^cUrine creatinine not done, protein expressed in mg/dL urine.